{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:38:17Z","timestamp":1763037497326,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.numecd.2020.06.028","type":"journal-article","created":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T02:22:13Z","timestamp":1593656533000},"page":"2027-2035","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Evolving trend in the management of heterozygous familial hypercholesterolemia in Italy: A retrospective, single center, observational study"],"prefix":"10.1016","volume":"30","author":[{"given":"Laura","family":"D'Erasmo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Commodari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8359-6599","authenticated-orcid":false,"given":"Alessia","family":"Di Costanzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9801-4501","authenticated-orcid":false,"given":"Ilenia","family":"Minicocci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7986-3260","authenticated-orcid":false,"given":"Luca","family":"Polito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4051-4922","authenticated-orcid":false,"given":"Fabrizio","family":"Ceci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Montali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Maranghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Arca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.numecd.2020.06.028_bib1","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S2213-8587(19)30156-1","article-title":"Practical definitions of severe versus familial hypercholesterolaemia and hypertriglyceridaemia for adult clinical practice","volume":"7","author":"Garg","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"27","key":"10.1016\/j.numecd.2020.06.028_bib2","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1093\/eurheartj\/ehy182","article-title":"European Atherosclerosis Society Consensus Panel. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract","volume":"39","author":"Mach","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2020.06.028_bib3","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"issue":"45","key":"10.1016\/j.numecd.2020.06.028_bib4","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.numecd.2020.06.028_bib5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.atherosclerosis.2009.09.014","article-title":"Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands","volume":"209","author":"Pijlman","year":"2010","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.numecd.2020.06.028_bib6","first-page":"744","article-title":"Prevalence and Treatment of Familial Hypercholesterolemia in France","volume":"35","author":"B\u00e9rard","year":"2019","journal-title":"Can J Cardiol"},{"issue":"9","key":"10.1016\/j.numecd.2020.06.028_bib7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11883-019-0797-3","article-title":"The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: results from the ScreenPro FH Project","volume":"21","author":"Ceska","year":"2019","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.numecd.2020.06.028_bib8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.atherosclerosis.2018.08.008","article-title":"Real-life LDL-C treatment targets achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: results of the PLANET registry","volume":"277","author":"Vrablik","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2020.06.028_bib9","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.atherosclerosis.2018.08.017","article-title":"Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH)","volume":"277","author":"Rizos","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2020.06.028_bib10","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.atherosclerosis.2018.08.050","article-title":"Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: the CaReHigh Registry","volume":"277","author":"Schmidt","year":"2018","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.numecd.2020.06.028_bib11","first-page":"1004","article-title":"Attainment of recommended lipid targets in patients with familial hypercholesterolemia: real-world experience with PCSK9 inhibitors","volume":"34","author":"Razek","year":"2018","journal-title":"Can J Cardiol"},{"issue":"3","key":"10.1016\/j.numecd.2020.06.028_bib12","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1161\/CIRCRESAHA.118.313238","article-title":"cholesterol-lowering agents","volume":"124","author":"Rosenson","year":"2019","journal-title":"Circ Res"},{"issue":"3","key":"10.1016\/j.numecd.2020.06.028_bib13","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jacc.2018.04.054","article-title":"The evolving future of PCSK9 inhibitors","volume":"72","author":"Rosenson","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"10.1016\/j.numecd.2020.06.028_bib14","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.numecd.2020.06.028_bib15","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab andcardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.numecd.2020.06.028_bib16","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jacl.2019.07.005","article-title":"PCSK9 inhibition, atherosclerotic cardiovascular disease, and health economics: challenges at the crossroads","volume":"13","author":"Annemans","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.numecd.2020.06.028_bib17","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jacl.2017.04.120","article-title":"Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: results of a healthcare provider survey conducted by the National Lipid Association","volume":"11","author":"Cohen","year":"2017","journal-title":"J Clin Lipidol"},{"issue":"5","key":"10.1016\/j.numecd.2020.06.028_bib18","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/CIRCRESAHA.117.311532","article-title":"Application of PCSK9 inhibitors in practice: challenges and opportunities","volume":"121","author":"Kaufman","year":"2017","journal-title":"Circ Res"},{"issue":"2","key":"10.1016\/j.numecd.2020.06.028_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009220","article-title":"Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal","volume":"5","author":"Huijgen","year":"2010","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.numecd.2020.06.028_bib20","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/HCO.0000000000000660","article-title":"Screening and management of familial hypercholesterolemia","volume":"34","author":"Santos","year":"2019","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.numecd.2020.06.028_bib21","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.atherosclerosis.2018.08.013","article-title":"Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: the LIPIGEN study","volume":"277","author":"Casula","year":"2018","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.numecd.2020.06.028_bib22","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1038\/s41598-018-21939-0","article-title":"Evaluation of polygenic determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a candidate genes resequencing strategy","volume":"8","author":"Di Costanzo","year":"2018","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.numecd.2020.06.028_bib23","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/gim.2017.151","article-title":"Analysis of publicly available LDLR, APOB, and PCSK9 variants associated with familial hypercholesterolemia: application of ACMG guidelines and implications for familial hypercholesterolemia diagnosis","volume":"20","author":"Chora","year":"2018","journal-title":"Genet Med"},{"issue":"2","key":"10.1016\/j.numecd.2020.06.028_bib24","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1373\/clinchem.2017.279422","article-title":"Clin chem imputation of baseline LDL cholesterol concentration in patients with familial hypercholesterolemia on statins or ezetimibe","volume":"64","author":"Ruel","year":"2018","journal-title":"Clin Chem"},{"issue":"3","key":"10.1016\/j.numecd.2020.06.028_bib25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jacc.2017.11.028","article-title":"Autosomal recessive hypercholesterolemia: long-term cardiovascular outcomes","volume":"71","author":"D'Erasmo","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.numecd.2020.06.028_bib26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.atherosclerosis.2015.03.002","article-title":"IMPROVE-IT clinical implications. Should the \"high-intensity cholesterol-lowering therapy\" strategy replace the \"high-intensity statin therapy\"?","volume":"240","author":"Masana","year":"2015","journal-title":"Atherosclerosis"},{"issue":"39","key":"10.1016\/j.numecd.2020.06.028_bib28","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"ESC scientific document group, 2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2020.06.028_bib32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.atherosclerosis.2017.11.027","article-title":"PCSK9 inhibitors in clinical practice: delivering on the promise?","volume":"270","author":"Stoekenbroek","year":"2018","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.numecd.2020.06.028_bib33","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13032","article-title":"Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres","volume":"71","author":"Kohli","year":"2017","journal-title":"Int J Clin Pract"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475320302726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475320302726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:13:28Z","timestamp":1760544808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475320302726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0939475320302726"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2020.06.028","relation":{},"ISSN":["0939-4753"],"issn-type":[{"type":"print","value":"0939-4753"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolving trend in the management of heterozygous familial hypercholesterolemia in Italy: A retrospective, single center, observational study","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2020.06.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}